Improved local delivery of TGF-?2 by binding to injectable fibrillar collagen via difunctional polyethylene glycol

Bentz, Hanne; Schroeder, J. A.; Estridge, Trudy D.

doi:10.1002/(sici)1097-4636(19980315)39:4<539::aid-jbm6>3.0.co;2-k

Cited by 93 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the actual amounts of Tgf-␤3 released from the collagen gel were not quantified in the perisutural tissues, and the sutures in the Tgf-␤3 groups may have received smaller amounts than anticipated. However, studies using this collagen gel vehicle have shown that Tgf-␤2 mixed with the collagen gel in culture retained a level of activity similar to that of Tgf-␤2 alone (Schroeder-Tefft et al, 1997;Bentz et al, 1998). The collagen lasted for at least 63 days in rabbit perisutural tissue, as observed by the use of biotinylated collagen gel (Moursi et al, unpublished data), and it showed no evidence of a localized inflammatory or generalized immune response following gel implantation (Chong et al, 2001(Chong et al, , 2002Mooney et al, 2002a;Opperman et al, 2002b) (Moursi et al, unpublished data).…”

Section: Discussionmentioning

confidence: 99%

Rescue of coronal suture fusion using transforming growth factor‐beta 3 (Tgf‐β3) in rabbits with delayed‐onset craniosynostosis

et al. 2003

View full text Add to dashboard Cite

Craniosynostosis results in cranial deformities and increased intracranial pressure, which pose extensive and recurrent surgical management problems. Developmental studies in rodents have shown that low levels of transforming growth factor-␤3 (Tgf-␤3) are associated with normal fusion of the interfrontal (IF) suture, and that Tgf-␤3 prevents IF suture fusion in a dose-dependent fashion. The present study was designed to test the hypothesis that Tgf-␤3 can also prevent or "rescue" fusing sutures in a rabbit model with familial craniosynostosis. One hundred coronal sutures from 50 rabbits with delayed-onset, coronal suture synostosis were examined in the present study. The rabbits were divided into five groups of 10 rabbits each: 1) sham controls, 2) bovine serum albumin (BSA, 500 ng) low-dose protein controls, 3) low-dose Tgf-␤3 (500 ng), 4) high-dose BSA (1,000 ng) controls, and 5) high-dose Tgf-␤3 (1,000 ng). At 10 days of age, radiopaque amalgam markers were implanted in all of the rabbits on either side of the coronal suture to monitor sutural growth. At 25 days of age, the BSA or Tgf-␤3 was combined with a slow-absorbing collagen vehicle and injected subperiosteally above the coronal suture. Radiographic results revealed that high-dose Tgf-␤3 rabbits had significantly greater (P Ͻ 0.05) coronal suture marker separation than the other groups. Histomorphometric analysis revealed that high-dose Tgf-␤3 rabbits also had patent coronal sutures and significantly (P Ͻ 0.01) greater sutural widths and areas than the other groups. The results suggest that there is a dose-dependent effect of TGF-␤3 on suture morphology and area in these rabbits, and that the manipulation of such growth factors may have clinical applications in the treatment of craniosynostosis. Anat Rec Part A 274A: 962-971, 2003.

show abstract

Section: Discussionmentioning

confidence: 99%

Rescue of coronal suture fusion using transforming growth factor‐beta 3 (Tgf‐β3) in rabbits with delayed‐onset craniosynostosis

et al. 2003

View full text Add to dashboard Cite

show abstract

“…[212] Also, recombinant TGF-b2, when covalently bound to fibrillar collagen (FC) via a difunctional PEG linker, was found to be more prolonged and stabilized in its effects both in vivo and in vitro. [213] Using a gradient maker based on photopolymerization of a gradient flow, the spatial distribution of growth factors can be controlled. [214] The potential importance of this control has been demonstrated by the finding that attachment of randomly distributed TGF-b on PEG gels increased matrix production by smooth muscle cells [215] while attachment of bFGF in a gradient fashion directed cell alignment and migration.…”

Section: Immobilizing Growth Factors To the Matrixmentioning

confidence: 99%

Controlled Growth Factor Delivery for Tissue Engineering

2009

View full text Add to dashboard Cite

Growth factors play a crucial role in information transfer between cells and their microenvironment in tissue engineering and regeneration. They initiate their action by binding to specific receptors on the surface of target cells and the chemical identity, concentration, duration, and context of these growth factors contain information that dictates cell fate. Hence, the importance of exogenous delivery of these molecules in tissue engineering is unsurprising, considering their importance for tissue regeneration. However, the short half-lives of growth factors, their relatively large size, slow tissue penetration, and their potential toxicity at high systemic levels, suggest that conventional routes of administration are unlikely to be effective. In this review, we provide an overview of the design criteria for growth factor delivery vehicles with respect to the growth factor itself and the microenvironment for delivery. We discuss various methodologies that could be adopted to achieve this localized delivery, and strategies using polymers as delivery vehicles in particular.

show abstract

“…In an illustrative study, covalent bonding of VEGF and angiopoietin to porous collagen scaffolds was accomplished using 1-ethyl-3-(3-dimethylamino propyl) carbodiimide hydrochloride (EDC) chemistry [51,52]. Alternatively, VEGF and Transforming Growth Factor β2 (TGFβ2) have been conjugated to collagen scaffolds using various bifunctional cross-linkers [53,54]. As another promising approach that models native GF-ECM interactions, collagen scaffolds have been covalently decorated with heparin, followed by the noncovalent attachment of GFs that naturally harbor heparin-binding domains [55–57].…”

Section: Functionalizing Bone-mimetic Scaffolds With Growth Factorsmentioning

confidence: 99%

Taking cues from the extracellular matrix to design bone-mimetic regenerative scaffolds

et al. 2016

View full text Add to dashboard Cite

There is an ongoing need for effective materials that can replace autologous bone grafts in the clinical treatment of bone injuries and deficiencies. In recent years, research efforts have shifted away from a focus on inert biomaterials to favor scaffolds that mimic the biochemistry and structure of the native bone extracellular matrix (ECM). The expectation is that such scaffolds will integrate with host tissue and actively promote osseous healing. To further enhance the osteoinductivity of bone graft substitutes, ECM-mimetic scaffolds are being engineered with a range of growth factors (GFs). The technologies used to generate GF-modified scaffolds are often inspired by natural processes that regulate the association between endogenous ECMs and GFs. The purpose of this review is to summarize research centered on the development of regenerative scaffolds that replicate the fundamental collagen-hydroxyapatite structure of native bone ECM, and the functionalization of these scaffolds with GFs that stimulate critical events in osteogenesis.

show abstract

Improved local delivery of TGF-?2 by binding to injectable fibrillar collagen via difunctional polyethylene glycol

Cited by 93 publications

References 17 publications

Rescue of coronal suture fusion using transforming growth factor‐beta 3 (Tgf‐β3) in rabbits with delayed‐onset craniosynostosis

Rescue of coronal suture fusion using transforming growth factor‐beta 3 (Tgf‐β3) in rabbits with delayed‐onset craniosynostosis

Controlled Growth Factor Delivery for Tissue Engineering

Taking cues from the extracellular matrix to design bone-mimetic regenerative scaffolds

Contact Info

Product

Resources

About